Damora Therapeutics, Inc. Common Stock (DMRA) Financials

DMRA’s financial statements show a well-funded but pre-revenue biotechnology company with substantial ongoing losses and heavy reliance on equity financing. The data provided identifies the issuer as Galecto, Inc., although the requested company name is Damora Therapeutics, Inc.; investors should verify the ticker and issuer details before relying on this analysis.

Revenue has remained at $0 in every reported income statement period provided, including Q2 2026. As a result, operating performance continues to be driven almost entirely by research and development spending rather than commercial sales.

• Strong liquidity: Cash and equivalents reached $540.5 million at the end of Q2 2026, up from $532.9 million in Q1 2026 and only $7.6 million below the quarter’s beginning cash after operating and financing activity.
• Low balance-sheet leverage: Total liabilities were $27.6 million against $543.6 million of assets, giving the company a large current liquidity cushion and limited traditional debt exposure.
• Operating cash burn remains manageable relative to cash: Q2 2026 operating cash outflow was $21.9 million. At that quarterly rate, the reported cash balance represents roughly six quarters of operating funding before considering future financing, investment returns or changes in spending.
• Research spending supports the development pipeline: R&D expense increased to $25.5 million in Q2 2026 from $23.8 million in Q1, indicating continued investment in clinical and research programs.
• Financing has significantly strengthened the balance sheet: The company raised $295.9 million through common equity issuance in Q1 2026 and another $50.9 million in Q2. This explains the sharp increase in cash from less than $10 million in Q3 2025 to more than $540 million in Q2 2026, but the benefit must be weighed against dilution.
• Investing activity has been limited recently: Q1 2026 reported no investing cash flow, while Q2 included only $1.6 million of investing-related cash activity. The company is therefore primarily preserving cash rather than expanding through capital expenditures or acquisitions.
• No revenue or gross profit has been generated: With no reported sales, the company has no operating revenue stream to offset research, administrative or financing costs.
• Losses have widened materially: Net loss attributable to common shareholders was $31.2 million in Q2 2026, compared with $27.8 million in Q1 and $2.9 million in the restated Q2 2025 period. Q2 operating expenses totaled $35.0 million, including $25.5 million of R&D and $9.5 million of selling, general and administrative costs.
• Operating cash burn has accelerated: Operating cash outflow increased from $2.4 million in Q1 2025 and $2.6 million in Q3 2025 to $20.6 million in Q1 2026 and $21.9 million in Q2 2026. The increase suggests a substantially higher spending base following the company’s financing and corporate restructuring activities.
• Severe dilution is a major shareholder risk: Weighted-average basic shares rose from approximately 1.1 million in 2024 and 2025 periods to 34.3 million in Q1 2026 and 61.1 million in Q2 2026. The company also carries $130.0 million of preferred stock, while retained earnings were negative $546.3 million, reflecting accumulated losses and a capital structure that may continue to change.

Overall, the balance sheet is substantially stronger than it was in 2023–2025, when cash balances generally ranged from approximately $7 million to $23 million and operating cash outflows were common. However, that improvement came primarily from large equity raises rather than operating progress. For investors, the key questions are whether the company can convert its elevated R&D spending into successful clinical outcomes and whether its cash runway will be sufficient without another dilutive financing.